Repositioning Candidate Details
| Candidate ID: | R0100 |
| Source ID: | DB00369 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cidofovir |
| Synonyms: | |
| Molecular Formula: | C8H14N3O6P |
| SMILES: | NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1 |
| Structure: |
|
| DrugBank Description: | Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis.[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223] |
| CAS Number: | 113852-37-2 |
| Molecular Weight: | 279.187 |
| DrugBank Indication: | For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) |
| DrugBank Pharmacology: | Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. |
| DrugBank MoA: | Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. |
| Targets: | DNA polymerase catalytic subunit |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |